Abstract: The present invention provides a substrate for purifying a biological liquid comprising a solid phase onto which molecules of at least one oligosaccharide that is capable of binding to one or more antibodies are grafted by covalent bonding, said solid phase carrying free aldehyde functions —CHO, a method of producing such a substrate, the use of such a substrate to stabilize the antibody/oligosaccharide bond, as well as a method of purifying a biological liquid in which the biological liquid is brought into contact with at least one substrate of the invention, in a manner such as to obtain the capture of antibodies present in said biological liquid by binding with at least certain of the molecules of oligosaccharide(s) grafted onto the solid phase.

Abstract: The present invention concerns a method of purifying a biological liquid comprising antibodies corresponding to whole human or animal blood or to a product obtained from human or animal blood, by bringing a biological liquid into contact with at least one substrate comprising a solid phase onto which molecules of at least one oligosaccharide are grafted by covalent bonding, the molecules of the at least one oligosaccharide being capable of binding to one or more of said antibodies present in said biological liquid, in a manner such as to capture at least a portion of said antibodies present in said biological liquid by binding with at least certain of the molecules of oligosaccharide(s) grafted onto said solid phase, characterized in that said solid phase carries free aldehyde functions —CHO.

Abstract: The present invention concerns a method of purifying a biological liquid comprising antibodies corresponding to whole human or animal blood or to a product obtained from human or animal blood, by bringing a biological liquid into contact with at least one substrate comprising a solid phase onto which molecules of at least one oligosaccharide are grafted by covalent bonding, the molecules of the at least one oligosaccharide being capable of binding to one or more of said antibodies present in said biological liquid, in a manner such as to capture at least a portion of said antibodies present in said biological liquid by binding with at least certain of the molecules of oligosaccharide(s) grafted onto said solid phase, characterized in that said solid phase carries free aldehyde functions —CHO.

Abstract: The present invention provides a substrate for purifying a biological liquid comprising a solid phase onto which molecules of at least one oligosaccharide that is capable of binding to one or more antibodies are grafted by covalent bonding, said solid phase carrying free aldehyde functions —CHO, a method of producing such a substrate, the use of such a substrate to stabilize the antibody/oligosaccharide bond, as well as a method of purifying a biological liquid in which the biological liquid is brought into contact with at least one substrate of the invention, in a manner such as to obtain the capture of antibodies present in said biological liquid by binding with at least certain of the molecules of oligosaccharide(s) grafted onto the solid phase.

Abstract: The present invention relates to polysaccharides selected from sulphated arabinogalactans, apiogalacturonans and sulphated heteroglycans intended to be used as a drug for the preventive or curative treatment of an influenza virus, as well as to the pharmaceutical compositions including, in particular in combination with at least one pharmaceutically acceptable carrier: either an extract of Codium fragile, including sulphated arabinogalactans, or an extract of Zostera marina or Lemna minor, including apiogalacturonans, or an extract of Caulerpa racemosa, including sulphated heteroglycans.

Abstract: The present invention relates to polysaccharides selected from sulphated arabinogalactans, apiogalacturonans and sulphated heteroglycans intended to be used as a drug for the preventive or curative treatment of an influenza virus, as well as to the pharmaceutical compositions including, in particular in combination with at least one pharmaceutically acceptable carrier: either an extract of Codium fragile, including sulphated arabinogalactans, or an extract of Zostera marina or Lemna minor, including apiogalacturonans, or an extract of Caulerpa racemosa, including sulphated heteroglycans.